Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Petrelli

Showing results (11-20 of 348) with videos related to

Pageof 35
Sort By:
Breast Cancer Research and Treatment|November 2, 2013
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancerFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro Barni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
PISCES trial: the end does not always justify the meansSandro Barni, Fausto Petrelli
Medical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro Barni
Journal of Thoracic Disease|October 30, 2018
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?Melissa Bersanelli, Fausto Petrelli
Translational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro Barni
Clinical Genitourinary Cancer|August 20, 2024
Metastatic Prostate Cancer: Sequential or Combination Therapy?Lorenzo Dottorini, Fausto Petrelli
Head & Neck|September 29, 2011
Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysisFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|December 17, 2010
Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?Fausto Petrelli, Sandro Barni
Pageof 35

Showing results (11-20 of 348) with videos related to

Sort By:
Pageof 35
Breast Cancer Research and Treatment|November 2, 2013
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancerFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro Barni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
PISCES trial: the end does not always justify the meansSandro Barni, Fausto Petrelli
Medical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro Barni
Journal of Thoracic Disease|October 30, 2018
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?Melissa Bersanelli, Fausto Petrelli
Translational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro Barni
Clinical Genitourinary Cancer|August 20, 2024
Metastatic Prostate Cancer: Sequential or Combination Therapy?Lorenzo Dottorini, Fausto Petrelli
Head & Neck|September 29, 2011
Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysisFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|December 17, 2010
Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?Fausto Petrelli, Sandro Barni
Pageof 35